Aaron Kantoff - Net Worth and Insider Trading
Aaron Kantoff Net Worth
The estimated net worth of Aaron Kantoff is at least $2 Million dollars as of 2024-09-20. Aaron Kantoff is the Director of Tourmaline Bio Inc and owns about 45,391 shares of Tourmaline Bio Inc (TRML) stock worth over $1 Million. Aaron Kantoff is also the Director of Centessa Pharmaceuticals PLC and owns about 60,000 shares of Centessa Pharmaceuticals PLC (CNTA) stock worth over $951,600. Details can be seen in Aaron Kantoff's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Aaron Kantoff has not made any transactions after 2023-10-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Aaron Kantoff
Aaron Kantoff Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Aaron Kantoff owns 2 companies in total, including Centessa Pharmaceuticals PLC (CNTA) , and Talaris Therapeutics Inc (TALS) .
Click here to see the complete history of Aaron Kantoff’s form 4 insider trades.
Insider Ownership Summary of Aaron Kantoff
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CNTA | Centessa Pharmaceuticals PLC | 2021-11-18 | director |
| TALS | Talaris Therapeutics Inc | 2023-10-19 | director |
Aaron Kantoff Latest Holdings Summary
Aaron Kantoff currently owns a total of 2 stocks. Among these stocks, Aaron Kantoff owns 45,391 shares of Tourmaline Bio Inc (TRML) as of October 24, 2023, with a value of $1 Million and a weighting of 51.88%. Aaron Kantoff also owns 60,000 shares of Centessa Pharmaceuticals PLC (CNTA) as of November 18, 2021, with a value of $951,600 and a weighting of 48.12%.
Latest Holdings of Aaron Kantoff
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TRML | Tourmaline Bio Inc | 2023-10-24 | 45,391 | 22.60 | 1,025,837 |
| CNTA | Centessa Pharmaceuticals PLC | 2021-11-18 | 60,000 | 15.86 | 951,600 |
Holding Weightings of Aaron Kantoff
Aaron Kantoff Form 4 Trading Tracker
According to the SEC Form 4 filings, Aaron Kantoff has made a total of 1 transactions in Tourmaline Bio Inc (TRML) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Tourmaline Bio Inc is the acquisition of 7,500 shares on October 24, 2023, which cost Aaron Kantoff around $88,950.
According to the SEC Form 4 filings, Aaron Kantoff has made a total of 1 transactions in Centessa Pharmaceuticals PLC (CNTA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Centessa Pharmaceuticals PLC is the acquisition of 10,000 shares on November 18, 2021, which cost Aaron Kantoff around $119,900.
Insider Trading History of Aaron Kantoff
- 1
Aaron Kantoff Trading Performance
GuruFocus tracks the stock performance after each of Aaron Kantoff's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Aaron Kantoff is 89.99%. GuruFocus also compares Aaron Kantoff's trading performance to market benchmark return within the same time period. The performance of stocks bought by Aaron Kantoff within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Aaron Kantoff's insider trading performs compared to the benchmark.
Performance of Aaron Kantoff
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 31.16 | | | | | |
| Relative Return to S&P 500(%) | 28.38 | | | | | |
Aaron Kantoff Ownership Network
Aaron Kantoff Owned Company Details
What does Centessa Pharmaceuticals PLC do?
Who are the key executives at Centessa Pharmaceuticals PLC?
Aaron Kantoff is the director of Centessa Pharmaceuticals PLC. Other key executives at Centessa Pharmaceuticals PLC include Chief Financial Officer Gregory M Weinhoff , director & Chief Executive Officer Saurabh Saha , and Chief People Officer Karen M. Anderson .
Centessa Pharmaceuticals PLC (CNTA) Insider Trades Summary
Over the past 18 months, Aaron Kantoff made no insider transaction in Centessa Pharmaceuticals PLC (CNTA). Other recent insider transactions involving Centessa Pharmaceuticals PLC (CNTA) include a net sale of 230,000 shares made by Saurabh Saha , a net sale of 85,000 shares made by Gregory M Weinhoff , and a net sale of 41,751 shares made by Harris Rotman .
In summary, during the past 3 months, insiders sold 315,000 shares of Centessa Pharmaceuticals PLC (CNTA) in total and bought 0 shares, with a net sale of 315,000 shares. During the past 18 months, 429,211 shares of Centessa Pharmaceuticals PLC (CNTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 429,211 shares.
Centessa Pharmaceuticals PLC (CNTA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Centessa Pharmaceuticals PLC Insider Transactions
Aaron Kantoff Mailing Address
Above is the net worth, insider trading, and ownership report for Aaron Kantoff. You might contact Aaron Kantoff via mailing address: C/o Centessa Pharmaceuticals Plc, D. Hodgkin Bldg, Babraham Rsrch Campus, Cambridge X0 Cb22 3fh.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
